FIELD: medicine.
SUBSTANCE: immunological detection and quantitative analysis of sequential changes in protein levels of VEGF-165 in obtained patient's samples taken in course of time are conducted, where increasing levels of the protein VEGF-165 in course of time indicate progression of disease or adverse reaction to the therapy, and where decreasing levels of protein VEGF-165 in course of time indicate remission of the disease or a positive reaction to the therapy.
EFFECT: method enables to conduct noninvasive analysis of levels of circulating VEGF-165 which serves as a valuable prognostic indicator of disease outcome.
22 cl, 2 dwg, 2 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
COMPOSITIONS AND METHODS OF TREATING AND DIAGNOSING CANCER-RESISTANT CANCER | 2015 |
|
RU2710735C2 |
BLOOD PLASMA BIOMARKERS APPLICABLE FOR COMBINATION THERAPIES WITH USING BEVACIZUMAB IN TREATING PANCREATIC CANCER | 2011 |
|
RU2582964C2 |
CANCER TREATMENT | 2015 |
|
RU2651469C1 |
BIOMARKERS FOR COMBINED THERAPY INCLUDING LENVATINIB AND EVEROLIMUS | 2016 |
|
RU2745060C2 |
BIOMARKERS BASED ON TUMOR TISSUE FOR COMBINED THERAPY WITH BEVACIZUMAB | 2011 |
|
RU2605282C2 |
METHOD FOR PREDICTION OF CLINICAL EFFECTIVENESS IN PATIENTS SUFFERING FROM LUNG CANCER | 2011 |
|
RU2526120C2 |
SELECTION OF MEDICATIONS FOR LUNG CANCER THERAPY BY MEANS OF ANTIBODY-BASED MATRICES | 2008 |
|
RU2519647C2 |
BIOMARKERS FOR PREDICTING AND ASSESSING RESPONSIVENESS OF ENDOMETRIAL CANCER SUBJECTS TO LENVATINIB COMPOUNDS | 2014 |
|
RU2658601C2 |
METHODS OF DIAGNOSIS AND COMPOSITION FOR CANCER TREATMENT | 2013 |
|
RU2666627C2 |
ANTI-VEGF/DLL4-IMMUNOGLOBULINS WITH DOUBLE VARIABLE DOMAINS AND THEIR APPLICATION | 2013 |
|
RU2636043C2 |
Authors
Dates
2010-07-20—Published
2006-10-20—Filed